

Special Issue

Recent Advances in Solid Retroperitoneal Tumors

Message from the Guest Editor

Retroperitoneal tumors are a common pathology and relatively frequent reason for surgery in high-volume, specialized centers. Due to the specificity of the retroperitoneal region it can often be quite difficult to perform radical removal. In malignant tumors compartment resection is often necessary. Adjuvant oncological therapy is often mandatory; recently there has been a growing conversation surrounding targeted therapy. In this modality, reading the tumor genome is crucial. Thanks to next-generation sequencing we are able to focus on specific gene therapy. In this Special Issue we would like to present a multidisciplinary approach to this heterogeneous group of patients, from diagnostic issues to specific immune therapy. There is no doubt that following the guidelines and using all new techniques is beneficial for the patient. This Special Issue is intended not only for surgeons, but also for radiologists, pathologists, gene specialist, oncologists, and for all who come into contact with patients who have been diagnosed with retroperitoneal mass.

- retroperitoneal tumor
- next-generation sequencing
- targeted therapy

Guest Editor

Prof. Dr. Jiří Moláček

Fakultní nemocnice Plzeň, Pilsen, Czech Republic

Deadline for manuscript submissions

closed (28 February 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/101883

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).